ангиотензин转化酶2通过氨酸- ангиотензин系统缓解肝纤维化
Bai-Wei Zhao1, Ying-Jia Chen2, Ruo-Peng Zhang1
1Department of Gastric Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou 510060, Guangdong Province, China.
World journal of gastroenterology
|March 11, 2024
概括
ангиотензин转化酶2 (ACE2) 可以缓解小鼠肝纤维化. 它通过调节肝星细胞自和影响氨酸-氨酸系统来实现这一目标,提供潜在的治疗标.
科学领域:
- 生物化学 生物化学
- 细胞生物学 细胞生物学
- 肝病学 肝病学是一种肝病学.
背景情况:
- 肝纤维化是一个重要的健康问题.
- 肝星细胞 (HSC) 在肝纤维化中起着关键作用.
- 自是一种参与HSC激活的细胞过程.
研究的目的:
- 调查 ангиотензин转化酶2 (ACE2) 在肝纤维化中的作用.
- 为了确定ACE2是否调节HSC自.
- 探索ACE2对肝纤维化中的氨酸 - 血管新生素系统的影响.
主要方法:
- 肝纤维化的体内小鼠模型.
- 评估肝脏组织学和纤维化标志物.
- 在HSC中对自标记物的分析.
- 测量氨酸 - ангиотензин 系统的组成部分.
主要成果:
- 在小鼠中,ACE2的使用改善了肝纤维化.
- 通过ACE2治疗,可以提高HSC细胞的自性调节.
- ACE2调节了renin-angiotensin系统关键组件的表达.
结论:
- ACE2显示出对肝纤维化的保护作用.
- 通过增强HSC自,ACE2可以改善肝纤维化.
- 由于ACE2对氨酸- ангиотензин系统的作用,因此有助于ACE2的抗纤维作用.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
636
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
636
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
Antihypertensive Drugs: Direct Renin Inhibitors
625
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
625
Antihypertensive Drugs: Angiotensin II Receptor Blockers
730
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
730
Hormonal Regulation
33.1K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
165
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165


